Gatifloxacin
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
rosiglitazone
Thiazolidinedione · Antidiabetic
ThiazolidinedioneAntidiabetic
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
6 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 8 →
- GatifloxacinSevereDatabaseDDInter
- LeflunomideSevereDatabaseDDInter
- LomitapideSevereDatabaseDDInter
- MipomersenSevereDatabaseDDInter
Mechanism
Rosiglitazone targets PPARγ.
Indications
Type 2 diabetesHyperglycemia in type 2 diabetes
Pharmacokinetics
Peak effect
2-3 h
Metabolism
Liver
Side effects
Common
Weight gainEdemaMacular edemaMild reduction of hematocrit
Serious
- Heart failure (increased incidence)
- Bone fracture (increased risk in women)
- Hepatic injury (rare case reports)
Drug interactions
Leflunomide
Severe
Database
Clinical effect not specified
Source: DDInter
Lomitapide
Severe
Database
Clinical effect not specified
Source: DDInter
Mipomersen
Severe
Database
Clinical effect not specified
Source: DDInter
Pexidartinib
Severe
Database
Clinical effect not specified
Source: DDInter
Teriflunomide
Severe
Database
Clinical effect not specified
Source: DDInter
Rifampin
Moderate
Textbook
Reduced efficacy of rosiglitazone.
Source: G&G 14e · p1036
Gemfibrozil
Moderate
Database
Increased plasma levels of rosiglitazone.
A dose reduction is suggested for rosiglitazone.
Source: DDInter
4 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Ask House about rosiglitazone
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team